CSCI vs. MRSN, NBRV, CUE, MURA, CELU, LIAN, RNTX, ITRM, CLNN, and KPTI
Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Mersana Therapeutics (MRSN), Nabriva Therapeutics (NBRV), Cue Biopharma (CUE), Mural Oncology (MURA), Celularity (CELU), LianBio (LIAN), Rein Therapeutics (RNTX), Iterum Therapeutics (ITRM), Clene (CLNN), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry.
COSCIENS Biopharma vs. Its Competitors
Mersana Therapeutics (NASDAQ:MRSN) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.
Mersana Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
COSCIENS Biopharma has a net margin of -194.50% compared to Mersana Therapeutics' net margin of -217.63%. COSCIENS Biopharma's return on equity of -101.01% beat Mersana Therapeutics' return on equity.
COSCIENS Biopharma has lower revenue, but higher earnings than Mersana Therapeutics. COSCIENS Biopharma is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mersana Therapeutics currently has a consensus price target of $5.20, suggesting a potential upside of 1,500.00%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Mersana Therapeutics is more favorable than COSCIENS Biopharma.
In the previous week, COSCIENS Biopharma had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for COSCIENS Biopharma and 1 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 1.87 equaled COSCIENS Biopharma'saverage media sentiment score.
93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Mersana Therapeutics beats COSCIENS Biopharma on 10 of the 16 factors compared between the two stocks.
Get COSCIENS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COSCIENS Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CSCI) was last updated on 6/27/2025 by MarketBeat.com Staff
Buy CSCI Stock Free CSCI Stock Alerts